Corporate governance
Articles of Association
Articles of Association EQL Pharma AB (publ) Org.nr. 556713-3425
§1 Company
The company is EQL Pharma AB. The company is public (publ).
§2 Seat of the Board
The Board shall have its seat in Lund municipality.
§ 3 Activities
The limited company’s operations shall be to manufacture, develop, trade in medical, diagnostic, pharmaceutical and chemical-technical products, acquire and grant licenses and agencies for such products and activities compatible therewith. The company must also engage in financial activities, except for activities referred to in the Banking Act or the Credit Market Companies Act.
§ 4 Share Capital
The share capital shall amount to a minimum of SEK 534,897 and a maximum of SEK 2,139,588.
§ 5 Number of Shares
The number of shares shall be a minimum of 11,886,600 and a maximum of 47,564,600.
§ 6 Board
The Board shall consist of a minimum of three and a maximum of eight Board members with a maximum of three deputies.
§ 7 Auditor
For review of the company’s annual report and the administration of the Board and the Managing Director, two auditors, with or without deputies, are appointed or a registered auditing company.
§ 8 Notice of Annual General Meeting
Notice of a General Meeting shall always be given by advertising in Post-och Inrikes Tidningar and on the company’s website. That a summons has been issued shall be announced in Svenska Dagbladet. If the publication of Svenska Dagbladet were to cease, the advertising would instead take place through Dagens Industri.
§ 9 Registration for the meeting
Shareholders who have been entered in the share register in the manner prescribed in Chapter 7, Section 28, Paragraph 3 of the Swedish Companies Act and who have registered with the company no later than the date specified in the notice convening the meeting have the right to participate in the meeting. This day may not be Sunday, another public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not fall earlier than the fifth weekday before the meeting. If shareholders intend to bring assistants, the number of assistants must be stated in the notification.
§ 10 Annual General Meeting
The Annual General Meeting shall be held annually within six (6) months after the end of the financial year. The following matters shall be discussed at the Annual General Meeting:
1) Election of chairman at the meeting.
2) Establishment and approval of the ballot paper.
3) Approval of the agenda.
4) Election of one or two adjusters.
5) Examination of whether the meeting has been duly convened.
6) Presentation of the annual report and auditor’s report as well as any case consolidated accounts and consolidated auditor’s report.
7) Decide on
a) approval of the income statement and balance sheet and, where applicable, the consolidated income statement and consolidated balance sheet;
b) on dispositions regarding the company’s profit or loss according to the approved balance sheet and;
c) on discharge from liability of the members of the Board of Directors and the CEO.
8) Determination of the number of Board members, deputy Board members and of the number of auditors and deputy auditors.
9) Determination of fees to the Board and the auditors.
10) Election of the Board and any deputy Board members as well as auditors or auditing companies and any deputy auditors.
11) Other matters, which come to the meeting in accordance with the Swedish Companies Act or the Articles of Association.
§ 11 Financial year
The limited company’s financial year shall be 0401-0331.
§ 12 Reconciliation reservation
The shareholder or nominee who on the record date is entered in the share register and recorded in a record register, according to ch. the Act (1998: 1479) on the accounting of financial instruments or one that is recorded in a reconciliation account according to ch. § 18 first paragraph 6-8 mentioned law, shall be assumed to be competent that exercised rights set forth in Chapter 4. Section 39 of the Swedish Companies Act (2005: 551).
Corporate Governance Reports
2020/2021
A corporate governance report is coming soon.
Management

Axel Schörling
President and CEO
Education
MSc Engineering Physics, Chalmers and MSc Financial Economics, School of Business in Gothenburg.
Born
1986
Holding
257113 shares and 400000 call options
Work experience
Axel Schörling has a background as a management consultant at BearingPoint and most recently came from a role as Director of Perstorp’s Business Controlling team. Overall, he has extensive experience from a number of industries and assignments in logistics and supply chain from an operational / financial perspective.

Martin Kristofferson
COO
Education
MSc Business Administration, Linköping University
Born
1978
Holding
15200 shares and 46000 call options
Work experience
Martin Kristofferson has held numerous Sourcing and Procurement positions in the life science industry, most recently as responsible for CMO and Medical Devices Procurement at Leo Pharma in Copenhagen. Martin has also lived and worked in India as part of the AstraZeneca Global Branded Generics initiative.

Anna Jönsson
CFO
Education
Degree from IHM Business School in economics and accounting
Born
1984
Holding
13 729
Work experience
Anna has more than ten years of experience from the accounting and auditing industry. She has worked as a qualified accounting consultant and office manager in Lund at Resursgruppen Ekonomi & Revision AB. Anna has previously been CFO for the listed companies Amniotics AB and Respiratorius AB.

Alexander Brising
Business Development Director
Education
MSc Business Administration, Management & Operations from the Gothenburg School of Economics
Born
1970
Holding
356 543
Work experience
Alexander Brising has held a number of marketing and business development assignments in the pharmaceutical industry, most recently coming from Sandoz Nordic Headquarters in Copenhagen and an assignment as Commercial Head Sweden.

Cornelia Lindström
Reg/QA/PV Director
Education
MSc Pharm, Leg. Pharmacist, Uppsala University
Born
1986
Holding
46000 call options
Work experience
Cornelia has extensive experience of Regulatory Affairs and Quality Assurance in various positions in the pharmaceutical industry and most recently came from a role as Head of Regulatory Affairs and Pharmacovigilance at Bayer Animal Health in Copenhagen.

Carl Lindgren
Chief Business Development Officer
Education
B.Sc., Business Administration and Economics, Lund University
Born
1968
Holding
None
Work experience
Carl Lindgren has more than 25 years of experience from the Life Science industry within multinational companies like AstraZeneca PLC, Lundbeck A/S and Karo Pharma AB. He most recently joined from a position as VP M&A/Business Development within the executive management team of Karo Healthcare AB. Carl is furthermore Member of the Board of Iconovo AB and Biomedica Norden AB.
Board of Directors

Christer Fåhraeus
Chairman of the Board
Education
BA, MSc Biotechnology, PhD hc
Born
1965
Holding
9 310 271 via companies
Independent
No
Assumed
Board member since 2006
Professional experience
Chairman of FlatFrog Laboratories AB, Respiratorius AB (plc) and Longboat Explorers AB. Member of the board of CellaVision AB (plc), LU Innovation AB and Reccan AB. Former CEO of CellaVision AB (plc), Anoto Group AB (plc), Flatfrog Laboratories and Agellis Group AB (plc).

Anders Månsson
Board member
Education
BSc & MBA
Born
1967
Holding
10 000
Independent
Yes
Assumed
Board member since 2018
Professional experience
With 25 years of experience in Life Sciences, Anders has held several Senior Executive roles in multinational pharmaceutical companies, both abroad and at home. He is currently CEO and Member of the Board of Longboat Amniotics AB, a private Biotech company operating in stem cell production & development. Anders is also a Board Member in Respiratorius AB (publ.), and Chairman of the Board in CanImGuide Theraputics AB (priv.). In addition, he serves as Industrial Advisor in Life Sciences to the Private Equity company Ratos AB (publ.).

Per Ollermark
Board member
Education
BSC
Born
1960
Holding
No
Independent
Yes
Assumed
Board member since 2021
Professional experience
More than 25 years of experience from leading finance positions in international groups, both abroad and in Sweden, the majority of which are companies within Life Science. For 10 years, interim consultant and financial advisor via his own company Turn the Key AB, with a focus on efficiency projects, turn-around, IPO preparations and traditional interim roles.

Per Svangren
Board member
Education
Pharmacist, Uppsala University
Born
1973
Holding
10 480
Independant
Yes
Assumed
Board member since 2021
Professional experience
Currently senior consultant and CEO of own consulting company Svangren Life Science Consulting AB. Has >20 years of experience in the Pharma and Med Tech industry in both local and global positions. Previous employers include Pfizer, AstraZeneca, LEO Pharma and SOBI. Ended assignment in Barsebäck Golf Country Club in March 2021 after 7 years on its board.

Rajiv I. Modi
Board member
Education
MSc Biochemical Engineering from University College, London, PhD Biological Science from the University of Michigan, Ann Arbor, USA.
Born
1960
Holding
8 718 500 via company
Independant
No
Assumed
Board member since 2015
Professional experience
Chairman and Managing Director of Cadila Pharmaceuticals.
Cadila Pharmaceuticals places immense focus on research. Being a Biotechnologist himself, Dr Modi has played a major role in developing the Company’s Biotechnology Division into a strong R&D unit, focusing on new developments and breakthrough innovations. Envisioning a global presence for the Group, Dr Modi played a pivotal role in establishing the marketing set-up and subsidiaries of the Company across the shores.
Chairman of the CII National Committee on Pharma 2015-2016. Chairman of Board of Governance of Indian Institute of Technology, Guwahati, India. Former Chairman of CII Gujarat State Council.

Linda Neckmar
Board member
Education
M.Sc. (Chemical Engineering) Lund University of Technology
Born
1973
Holding
2 500
Independant
Yes
Assumed
Board member since 2020
Professional experience
Head of Commercial Development på Chr Hansen AS. Styrelseledamot i Veg of Lund AB. Tidigare VP EMEA and APAC på Probi AB och styrelseledamot i Phase Holographic Imaging AB.
Nomination Committee
Main principles shall apply for the composition of the Nomination Committee:
The Chairman of the Board shall, as soon as registered shareholders of the company is known per December 31, contact the three with the most voting power according to the company’s shareholder’s registry and ask them to provide one member each for the Nomination Committee. If one such shareholder doesn’t wish to provide a member, the next shareholder in voting power is asked until all three seats are taken. The thus chosen members will make up the Nomination Committee. The Chairman of the Board will gather, but not be part of, the Nomination Committee, however the Committee might choose to adjunct the Chairman to help in the nomination preparations. The Nomination Committee shall thereafter choose a chairman for the Committee from amongst its members. The names of the members of the Nomination Committee shall be published by the company six months prior to the General Annual Meeting at the latest.
If a shareholder, that have a chosen member on the Nomination Committee and before the work of the Committee has finished, would get a lower ranking among the shareholders with the most voting power. The member that that shareholder has provided can, at the decision of the Committee, be replaced by a new member as provided by the shareholder with, at that point, larger voting power that are not already represented in the Committee. If one of the Committee’s members, before the Committee’s task is complete, choose to retire from the Committee or otherwise stop being a representative of the nominating shareholder, then a new member can be appointed by this shareholder if the shareholder so wishes.
The thus appointed Nomination Committee will be active until the next Nomination Committee has been appointed. The members of the Nomination Committee will receive no compensation for their work in the Committee. The company will, as needed, reimburse the Committee for costs that has been deeemed neccessary by the Committee for it to fulfill its tasks. The Nomination Committee can also adjunct members to the Committee if it deems it prudent; the adjuncted member will not, however, have any voting power in the Committee.
Auditors
Auditing company: Deloitte AB
Responsible auditor: Maria Ekelund